Aortic aneurysm rupture is a significant cause of premature mortality worldwide. Although animal models exist, some frequently experience aortic rupture and sudden death. An alternative approach is therefore required that would use human material to aid translation. Accordingly, we present an optimized and validated protocol to isolate human umbilical cord arteries and their subsequent deployment within a bioreactor. Consequently, this reproducible ex vivo human model of aneurysm can be used for pathogenesis studies and accompanying assessment of potential novel therapeutics.
Protocol
A Protocol for a Novel Human Ex Vivo Model of Aneurysm

Rosaria Bianco,1,2,* Karina Di Gregoli,1 Massimo Caputo,1 Sarah J. George,1 and Jason L. Johnson1,3,*

1Laboratory of Cardiovascular Pathology, Department of Translational Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK
2Technical Contact
3Lead Contact
*Correspondence: rosaria.bianco@bristol.ac.uk (R.B.), jason.l.johnson@bristol.ac.uk (J.L.J.)
https://doi.org/10.1016/j.xpro.2020.100108

SUMMARY
Aortic aneurysm rupture is a significant cause of premature mortality worldwide. Although animal models exist, some frequently experience aortic rupture and sudden death. An alternative approach is therefore required that would use human material to aid translation. Accordingly, we present an optimized and validated protocol to isolate human umbilical cord arteries and their subsequent deployment within a bioreactor. Consequently, this reproducible ex vivo human model of aneurysm can be used for pathogenesis studies and accompanying assessment of potential novel therapeutics.

BEFORE YOU BEGIN
The establishment of the ex vivo model of aneurysm formation requires the bioreactor to be set up, following these major steps:

Experimental Design Consideration

@ Timing: 2 h

1. Arrange umbilical cord delivery with the research nurse at the Maternity Hospital.
2. Arrange umbilical cord delivery with other research groups within the department.
3. Plan the experimental design in order to know how many chambers, lengths of tubing, and number of canulae are required.
4. Plan the conditions of scheduled treatments and interventions to be used and therefore the number of chambers that need to be set up.
5. Calculate the shear stress to be used. In abdominal aortic aneurysm (AAA) patients, the wall shear stress is between 3.6 to 9.2 dyn/cm². Accordingly, we use a wall shear stress of 6.5 dyn/cm² in a pulsatile laminar flow direction within the ex vivo model to ensure similar haemodynamic conditions to the abdominal segment of the human aorta.

Preparation of Bioreactor Components

@ Timing: 2 h

6. Tubing, autoclave, and medium
   a. Cut long silicon tubes into the correct length and connect to a stronger silicon tube. This additional strength is required to be used within the peristaltic pump. Connect all tubes together with cannula at both ends and then autoclave.
b. Cut short silicon tubes, connect to cannula at both ends and then autoclave.
c. Autoclave water, forceps, and sylgard dishes.
d. Obtain Dulbecco’s Modified Eagle’s Medium (DMEM) and supplement with gentamicin, penicillin, streptomycin, and L-glutamine.
e. Prepare a fresh formaldehyde.

Assembly of Bioreactor

⏰ Timing: 30 min

7. Bioreactor
   a. Place bioreactor chambers for at least 2 h in a Milton sterilizing solution, briefly wash in sterile water and then place under a tissue culture hood to dry (Figure 1A).
   b. Connect a long silicon tube at both ends to the bioreactor chamber (Figure 1B).
   c. Connect two short silicon tubes to the inner edges of the bioreactor chamber (Figure 1C).

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Biological Samples** | | |
| Umbilical cord arteries from human umbilical cord | St. Michael’s Maternity Hospital | N/A |
| **Chemicals, Peptides, and Recombinant Proteins** | | |
| Angiotensin II | Enzo Life Sciences | Cat#ALX-151-039 |
| Dulbecco’s modified Eagle’s medium (DMEM) | Sigma | Cat#D5546 |
| Fetal bovine serum (FBS) | ThermoFisher | Cat#10500-064 |
| Gentamicin | Sigma | Cat#G1397 |
| Penicillin and streptomycin | Sigma | Cat#P4333 |
| L-glutamine | Sigma | Cat#G7513 |
| PBS | Sigma | Cat#D8537 |
| Chloroform | Sigma | Cat#132950 |
| Clearene (xylene substitute) | Leica | Cat#3803600 |
| 100% alcohol | Leica | Cat#3803686 |
| Potassium permanganate | VWR | Cat#26904.293 |
| Oxalic acid | VWR | Cat#0326-500G |
| Millers elastin stain | VWR | Cat#351154S |
| Van Gieson stain | ThermoFisher | Cat#LAMB-400-D |
| Mayer’s hemotoxylin | VWR | Cat#1004710S |
| Scotts tap water | Sigma | Cat#55134 |
| Eosin Y | VWR | Cat#341972Q |
| Picosirius red solution | Abcam | Cat#ab246832 |
| Hydrochloric acid | Sigma | Cat#320331 |
| Citric acid | Sigma | Cat#251275 |
| DPX mounting medium | Sigma | Cat#06522 |
| BLOXALL endogenous blocking solution | Vector Labs | Cat#SP-6000 |

(Continued on next page)
**Materials and Equipment**

△ CRITICAL: All preparatory procedures need to be performed within a Class II biological hood with standard aseptic technique.

**Serum Free Dulbecco’s Modified Eagle’s Medium (SFM)**

Serum free Dulbecco’s Modified Eagle’s Medium (DMEM) is supplemented as detailed below. All supplements are added using a Minisart syringe filter to prevent fungal and bacterial infections, mixed well and finally stored at 4°C.

**Media composition for Serum Free DMEM**

| Reagent                        | Final Concentration | Amount |
|--------------------------------|---------------------|--------|
| Gentamicin                     | 400 µL/500 mL       | 100 µL |
| Penicillin and Streptomycin    | 100 µL/mL and 100 µL/mL | 5 mL  |
| L-glutamine                    | 2 mM                | 5 mL   |
| DMEM                           | n/a                 | 500 mL |
10% FBS/DMEM Culture Media
Serum free DMEM is supplemented with 50 mL fetal bovine serum (FBS) gold to obtain 10% FBS/DMEM. FBS is the most common growth supplement used for the in vitro and ex vivo cell culture. FBS has a high content of embryonic growth and therefore is always used for all our in vitro and ex vivo studies.

All the components of 10% FBS/DMEM are listed below. FBS is added using a Minisart syringe filter to prevent fungal and bacterial infections, mixed well and finally stored at 4°C.

### Media composition for 10% FBS/DMEM

| Reagent            | Final Concentration | Amount |
|--------------------|---------------------|--------|
| Fetal bovine Serum | 10%                 | 50 mL  |
| Gentamicin         | 400 μL/500 mL       | 100 μL |
| Penicillin and Streptomycin | 100 μL/mL and 100 μL/mL | 5 mL |
| L-glutamine        | 2 mM                | 5 mL   |
| DMEM               | n/a                 | 450 mL |

### Bioreactor Components

A Watson-Marlow Sci-Q 300 Series Peristaltic Pump from Thermo Fisher is used to generate a wall shear stress of 6.5 dyn/cm² in a laminar flow direction to induce the ex vivo aneurysmal model. A Wacker silicon tubing, ID 3.18MM, OD 6.35MM from VWR is used to connect either ends of the bioreactor chamber. A Cannula, Male Luer Fitting for 1/16” ID Tubing from World Precision Instrument is connected to the silicon tubing and then placed inside a supporting bioreactor chamber. A Suture, Mersilk 5-0 black from Ethicon is used to tie the artery onto the cannula.

### STEP-BY-STEP METHOD DETAILS

**CRITICAL:** Human umbilical cord samples must be obtained in compliance with institutional review board regulations and ethical guidelines. All procedures used for handling human tissues should assume potential contamination of tissue with human pathogens (HBV, HCV, HIV, C. difficile, etc.).

### Dissection of Arteries from Human Umbilical Cord

**Timing:** 2 h

This step details how to dissect the arteries from human umbilical cord (as shown in Figure 2).

1. Obtain human umbilical cords, covered under existing ethical approval.
a. Store umbilical cords in serum free media at 4°C immediately after being obtained.

b. Dissect umbilical cord samples, limiting the time between harvest and usage within the bioreactor setup to 90 ± 30 min.

2. Human umbilical cords contain two arteries and one vein surrounded by Wharton jelly.
   a. Under sterile conditions, place a length of umbilical cord within a sylgard petri dish.
   b. Identify the two arteries and one vein by observing a cross-section of the umbilical cord.

3. Partially open the cord and pin down on the dish (a flat surface is required to work on).

4. Micro-dissect the arteries under phosphate-buffered saline (PBS, pH 7.4) containing penicillin 100 U/mL and streptomycin 100 mg/mL at 4°C and flush with PBS to remove any possible blood clots before transferring into serum free DMEM at 4°C

5. Use the excised arteries immediately after the dissection to preserve vessel integrity and maintain experimental consistency.

Ex Vivo Model of Aneurysm

**Timing:** 3 h

This step details how to set up the bioreactor system for the ex vivo aneurysm model

6. Sterilize tissue culture hoods with a Milton sterilizing solution

7. Place bioreactor chambers in Milton sterilizing solution for at least 2 h, then briefly wash in sterile water and finally place under a tissue culture hood to dry.

8. Cut the arteries (stored in serum free DMEM at 4°C) into three equal lengths of 5 cm to be used for baseline, untreated, and treated conditions, respectively.

9. Connect the short silicon tubes at both ends of the bioreactor chamber.

10. Mount the arteries between two small cannulae, using sutures to double tie the artery onto each cannula.

11. Connect each cannula to the short silicon tube and then place inside a supporting bioreactor chamber.

12. Fill the long silicon tube with 10% FBS/DMEM and pass the tube through a peristaltic pump to close the system and permit the induction of laminar flow within an incubator.

13. Subject each chamber to identical pulsatile flow conditions with a flow rate of 6.5 dyn/cm² to closely mimic abdominal aortic in vivo conditions, at 37°C, 5% CO₂ for 72 h.

14. As a control, use untreated chambers with 80 mL of 10% FBS/DMEM. For Ang II-treated arteries, supplement 80 mL of 10% FBS/DMEM with 5 μM Angiotensin II. For intervention-treated chambers, add 80 mL of 10% FBS/DMEM with the corresponding intervention.

15. After 72 h of flow within the bioreactor chambers, carefully remove the arteries.

16. Remove and dispose of the two edges of the artery (not subjected to a laminar flow) where they were sutured to the cannula. Cut the artery cut into two segments, to be named as proximal and distal.
17. Fix the proximal segment in 10% formalin and prepare for histology and store the distal segment in a –80°C freezer for downstream genomic/proteomic analysis.

**Histological Processing: Elastin van Gieson Staining**

★ Timing: 3 h 30 min

18. The proximal portion of the artery (approx. 2.5 cm in length) should be cut into five 5 mm rings for subsequent histological processing and wax embedding.
19. From the formalin-fixed wax-embedded arterial rings, cut 3 μm sections collected upon adhesive glass microscope slides (two sections per slide).
20. To enable assessment of arterial elastin content, perform Elastin van Gieson (EVG) histochemical staining using an automated stainer (such as a Shandon Varistain 24-4 Automatic Slide Stainer) or manual protocol (protocol details are shown in Table 1).
21. After EVG staining, coverslip sections using a relevant mounting medium (such as DPX) and visualize the sections using a bright field microscope and acquire images under ×20 magnification.
22. Determine the relative amount of elastin (which appears as black under a light microscope) using a computerized image analysis program (such as Image Pro Plus or ImageJ) and express as an average percentage of the arterial cross-sectional area.

| Table 1. Staining Protocol for EVG |
|-----------------------------------|
| **Solution**                      | **Incubation Time** |
| Xylene substitute (such as Clearene) | 3 × 5 min          |
| 100% (v/v) alcohol (or industrial methylated spirits) | 3 × 5 min          |
| Tap water                          | 5 min              |
| 0.5% (w/v) potassium permanganate  | 10 min             |
| Distilled water                    | 3 min              |
| 1% (w/v) oxalic acid               | 5 min              |
| Distilled water                    | 3 min              |
| 70% (v/v) alcohol (or industrial methylated spirits) | 2 min          |
| 50% (v/v) Millers elastin stain (VWR, Cat#351154S) | 60 min          |
| 70% (v/v) alcohol (or industrial methylated spirits) | 2 min     |
| Running tap water                  | 3 min              |
| Van Gieson stain (ThermoFisher, LAMB-400-D) | 30 s             |
| 100% (v/v) alcohol (or industrial methylated spirits) | 3 × 5 min          |
| Xylene substitute (such as Clearene) | 3 × 5 min          |

**Histological Processing: Hematoxylin and Eosin Stain**

★ Timing: 1 h 30 min
23. From the formalin-fixed wax-embedded arterial rings, cut 3 μm sections collected upon adhesive glass microscope slides (two sections per slide).

24. To enable assessment of arterial cellular content and general morphology, perform haematoxylin and eosin (H&E) histochemical staining using an automated stainer (such as a Shandon Varistain 24-4 Automatic Slide Stainer) or manual protocol (protocol details are shown in Table 2).

25. After H&E staining, coverslip sections using a relevant mounting medium (such as DPX) and visualize the sections using a bright field microscope and acquire images under ×20 magnification.

26. Count the number of nuclei and express as an average percentage of the arterial cross-sectional area.

Table 2. Staining Protocol for H&E

| Solution                                      | Incubation Time |
|-----------------------------------------------|-----------------|
| Xylene substitute (such as Clearene)          | 3 × 5 min       |
| 100% (v/v) alcohol (or industrial methylated spirits) | 3 × 5 min       |
| Tap water                                     | 5 min           |
| Mayer’s Haematoxylin                          | 3 min           |
| Distilled water                               | 3 min           |
| Scott’s Tap water                             | 1 min           |
| Running tap water                             | 3 min           |
| 1% Eosin                                      | 1 min           |
| Running tap water                             | 3 min           |
| 100% (v/v) alcohol (or industrial methylated spirits) | 3 × 5 min       |
| Xylene substitute (such as Clearene)          | 3 × 5 min       |

Histological Processing: Picrosirius Red Staining

© Timing: 4 h

27. From the formalin-fixed wax-embedded arterial rings, cut 3 μm sections collected upon adhesive glass microscope slides (two sections per slide).

28. To enable assessment of arterial collagen content, perform picrosirius red (0.1% (w/v) Sirius Red F3B saturated aqueous picric acid, pH 1.8–2.2) histochemical staining (protocol details are shown in Table 3).

29. After picrosirius red staining, coverslip sections using a relevant mounting medium (such as DPX) and visualize the sections using a bright field polarizing microscope and acquire images under ×20 magnification.

30. Determine the relative amount of collagen (which appears as red under a light microscope) using a computerized image analysis program and express as an average percentage of the arterial cross-sectional area. Qualitative analysis of fiber thickness/age is assessed by delineating green and red fibers indicated under polarized light, as fiber color variation transits from green to red proportional to the increase of fiber thickness/age. The relative amount of each fiber color is expressed as a percentage of the total amount of collagen in the area of interest.
Table 3. Staining Protocol for Picrosirius Red

| Solution                                      | Incubation Time |
|-----------------------------------------------|-----------------|
| Xylene substitute (such as Clearene)          | 3 × 5 min       |
| 100% (v/v) alcohol (or industrial methylated spirits) | 3 × 5 min       |
| Distilled water                               | 3 × 2 min       |
| Picrosirius red solution 0.1% (w/v)           | 90 min          |
| 0.01 N hydrochloric acid                      | 2 × 15 s        |
| Distilled water                               | 2 × 2 min       |
| Oven dry at 37°C                               | 80 min          |
| 100% (v/v) alcohol (or industrial methylated spirits) | 1 × 5 min       |
| Xylene substitute (such as Clearene)          | 3 × 5 min       |

⚠️ CRITICAL: Ensure slides are dry before placing in 100% alcohol toward the end of the staining, as any residual water will cause the Picrosirius Red stain to leach from the section.

Histological Processing: Immunohistochemistry for Alpha-Smooth Muscle Actin and ER-TR7

⏰ Timing: 1 day

31. From the formalin-fixed wax-embedded arterial rings, cut 3 μm sections collected upon adhesive glass microscope slides (two sections per slide).
32. To enable assessment of vascular smooth muscle cell phenotypic modulation and density, and assess fibroblast presence, perform immunohistochemistry for alpha-smooth muscle actin (αSMactin) and ER-TR7 expression, respectively.

Dewax sections by placing in three changes of Clearene for the duration of 5 min in each.

33. Rehydrate sections by placing in three changes of graduated alcohol (100%, 90% and 70%) for the duration of 5 min in each.
34. Rinse in distilled H₂O.
35. Place slides in a black trough with 10 mM citrate acid pH 6.0 (2.1 g/L distilled H₂O)
36. 6 min full power in microwave
37. Top up with distilled water
38. 6 min full power in microwave
39. Top up with distilled water
40. Leave to cool for 30 min
41. Rinse in phosphate-buffered saline (PBS) for 3 × 2 min.
42. Dry back of slide with tissue paper and encircle sections with wax pen (ImmEdge Pen; Vector Labs; cat#H-400), place within a humidified chamber and then inhibit endogenous peroxidase activity with Bloxall endogenous blocking solution for 10 min at 18°C–22°C.
43. Rinse in PBS for 3 × 2 min, then pipette on 50 μL of 10% horse serum.
44. Incubate at 18°C–22°C for 30 min.
45. Tap off solution, dry back of slides and pipette on 50 μL of either mouse anti-human alpha-smooth muscle actin (1/200) or rat anti-human ER-TR7 (1/250), diluted in PBS. Use same species IgG diluted to same concentration as primary to act as a negative control.
46. Incubate for 16–18 h at 4°C.
47. Wash sections in PBS for 3 × 2 min.
48. Dry back of slides with tissue and pipette onto sections 50 μL of either horse anti-mouse biotinylated ready-to-use antibody (Vector Labs; cat#BP-2000) for alpha-smooth muscle actin.
detection, or goat anti-rat biotinylated ready-to-use antibody (Vector Labs; cat#BP-9400) for ER-TR7 detection, diluted 1/200 in PBS.

49. Incubate at 18°C–22°C for 30 min.
50. Wash sections in PBS for 3 × 2 min.
51. Dry back of slides with tissue and pipette onto sections 50 μL DyLight-488-conjugated Streptavidin (10 μg/mL; Vector Labs; cat#SA-5488).
52. Incubate at 18°C–22°C for 1 h.
53. Wash sections in PBS for 3 × 2 min.
54. Mount slides with appropriately sized coverslip and Vectashield antifade mounting medium with DAPI (Vector Labs; cat#H-1500) to enable the labeling of nuclei.

EXPECTED OUTCOMES

Following the above method, we have developed (and characterized) a reproducible ex vivo model of aneurysm formation with the use of human umbilical cord arteries stimulated with angiotensin II within a bioreactor system (summarized in Figure 3). Angiotensin II (Ang II) infusion is the most commonly used approach to induce aneurysm formation in animal models, especially mice, due to its ability to promote aneurysm formation with the most comparable histological features to those observed within human aneurysms (Sénémaud et al, 2017). Accordingly, angiotensin II infusion was therefore selected for use in our ex vivo model. The concentration of Ang II was established on the basis of previously published Ang II-infusion mouse model studies (Daugherty et al., 2000; Di Gregoli et al., 2017). Importantly, the dose used in our model was selected according to the range detected in human aneurysmal disease. The circulating Ang II level within healthy human subjects is between 4 and 15 pg/mL whereas AAA patients display plasma Ang II levels of 20–85 pg/mL. Within the ex vivo bioreactor model a concentration of 65 pg/mL was used, which is within the range detected in AAA patients.

Morphological and compositional changes typical of aneurysm formation have been widely characterized (Davies, 1998; Michel et al., 2011; Nordon et al., 2011), therefore a good model for aneurysm studies should display such characteristics, which includes vessel dilatation, medial thinning, elastin degradation, and loss of vascular smooth muscle cells.

As shown in Figure 4, umbilical cord arteries subjected to angiotensin II infusion for 72 h display marked macroscopically visible dilatation compared to a paired untreated control vessel. For the validation of our Ang II-infusion model, the umbilical cord artery was cut into three segments of equal length. One portion was flushed with PBS and inserted into a bioreactor system at 6.5 dyn/cm² using
media containing 5 \( \mu \text{M} \) Ang II in order to replicate the well-characterized mouse model of aneurysm formation. An equally sized length of the same umbilical cord artery was placed in the bioreactor system for 72 h at 6.5 dyn/cm\(^2\) with media alone and served as a paired control, termed untreated.

To ensure that the observed macroscopic changes were indicative of dilatation and therefore aneurysm formation, further histological examination was performed, as required to validate the model. As previously mentioned, the principle morphological and compositional characteristics associated with aneurysm formation were assessed, including vessel dilatation, medial thinning and associated elastin loss, and decreased medial vascular smooth muscle cell (VSMC) density.

As shown in Figure 5, Ang II infusion for 72 h under pulsatile laminar flow conditions demonstrated that the total vessel area (an indicator of dilatation) was significantly increased in Ang II-treated umbilical arteries (90%; \( P<0.05; n=6 \)) compared to untreated paired control arteries. In addition, a significant reduction in umbilical artery medial thickness (49%; \( P<0.05; n=6 \)), medial elastin content (60%; \( P<0.05; n=6 \)), and medial cell density (32%; \( P<0.05; n=5 \)) was observed in Ang II-treated umbilical arteries compared to paired untreated vessels. In summary, the above observations demonstrate our novel ex vivo bioreactor system employing arteries retrieved from human umbilical cord and subjected to Ang II administration, develops similar morphological and compositional changes associated with aneurysm formation as those observed in human aneurysms and mouse models. Assessment of these changes should be undertaken to validate the correct experimental setup of the model in new laboratory settings.

Two additional related key indicators of aneurysm formation are VSMC phenotypic modulation and increased collagen turnover. VSMC modulation from a contractile phenotype to a synthetic form is characterized by a loss of contractile markers such as alpha-smooth muscle actin (\( \alpha \text{SM actin} \)), which can be observed in umbilical cord arteries after Ang II administration within our ex vivo bioreactor model (Figure 6). However, very few fibroblasts (ER-TR7 positive) were detected (Figure 6).

Increased collagen turnover is most commonly presented as a reduction in arterial wall total collagen content. Accordingly, analysis of picrosirius red stained sections and subsequent quantification demonstrates a reduction of total fibrillar collagen content (32%; \( P<0.05; n=5 \); Figure 7) is an additional robust marker and validative indicator of aneurysm formation within our ex vivo bioreactor model.

**LIMITATIONS**

This model accurately reproduces key histological disease features observed in well-characterized animal models and the human pathology of aortic aneurysms, including vessel dilatation alongside compositional changes such as medial thinning, elastin degradation, and loss of VSMC content.
A potential limitation of the current model is the use of human umbilical cord arteries rather than the use of a human abdominal aorta. However, the structure and composition of the umbilical cord artery is similar to other arteries and it consists of three concentric layers: intima, media, and adventitia. The only marked difference is that umbilical arteries (similar to pulmonary arteries) carry deoxygenated blood which travels back to the placenta to be re-oxygenated again by the mother. The deoxygenated nature of the blood vessel (rather than oxygenated as is the case with the aorta) may affect the specific response to aneurysm inducers. However, the agreement in effects of Ang II on arterial changes in morphology and composition, between the \textit{ex vivo} model and both human aneurysms and the currently available mouse models suggest a high degree of similarity. As such, human umbilical cord arteries represent a good alternative to human aortic tissue and are more readily available for use in aneurysm research experiments. Considering the majority of human abdominal aortic aneurysms display super-imposed atherosclerosis and marked inflammatory cell accumulation (Davies, 1998; Michel et al., 2011; Nordon et al., 2011), an additional limitation of the \textit{ex vivo} model could be the absence of atherosclerosis-related inflammation. However, this is also a caveat with most mouse models of aneurysm and does not limit their use or publication in high impact journals. Moreover, the main intention of the \textit{ex vivo} model is to replicate and ideally replace current animal models of aneurysm, while also providing a more translational platform through the use of human tissue.
TROUBLESHOOTING

Problem 1
The ethics used during the development of this model and its subsequent validation covered projects from three different research groups. As such, there are occasions when human umbilical cords are shared between research groups, which can limit both the size and volume of samples. For example, a specific number of umbilical cords permitted to be retrieved and used in research under the ethical permission can hamper large experiments.

Potential Solution 1
If possible, have project-specific ethics in place which will allow use of the full length of the umbilical cord and ensure enough samples can be collected to fulfill the project requirements.

Problem 2
The cross-section thickness of the umbilical cord artery can be different between donors as well as between arteries from the same umbilical cord.

Potential Solution 2
We have to use a single umbilical cord artery and generate multiple segments from it at one time for control and intervention experiments. This will enable paired statistical analysis and reduce the intra-group variability resulting from the use of two different arteries of the same umbilical cord.

Problem 3
During the setup of the model, the small silicon tube is connected with a cannula to the umbilical cord artery within a chamber system. The chamber system is then connected at two points to a long silicon tube that is attached to the peristaltic pump. These factors are important to close the system and permit the induction of laminar flow within an incubator. If the arterial wall is damaged or the artery is not tied appropriately to the cannula, there will not be any laminar flow.

Figure 6. Effect of Ang II Administration on Arterial VSMC αSMA and ER-TR7 Immunopositivity
Representative images of immunohistochemistry for (A and B) alpha-smooth muscle actin (αSMA; green color) alongside a DAPI nuclear label (blue), or (C and D) ER-TR7 (green color) alongside a DAPI nuclear label (blue), in sections from human umbilical cord arteries after insertion within a bioreactor for 72 h without Ang II (untreated; A and C) and with Ang II (Ang II; B and D). Scale bar in (A) represents 50 μm and is applicable to all panels.
Potential Solution 3
In order to create consistent laminar flow, the arteries should be double tied at the two end points using appropriate surgical suture. If the arterial wall is damaged during this process, the damaged section should be discarded, and a new section of the same artery should be used.

RESOURCE AVAILABILITY

Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jason Johnson (jason.l.johnson@bristol.ac.uk).

Materials Availability
This study did not generate new unique reagents.

Data and Code Availability
This study did not generate any unique datasets or code.

ACKNOWLEDGMENTS
This work was supported by an NC3Rs/BHF PhD Studentship (NC/N003268/1) and a BHF Senior Research Fellowship awarded to J.L.J. (FS/18/1/33234).

AUTHOR CONTRIBUTIONS
R.B., K.D.G., and J.L.J. conducted the experiments; R.B. and J.L.J. analyzed the data and wrote the paper; M.C. secured the ethical permission; S.J.G. and J.L.J. supervised the project and conceptu- alized the study; M.C., S.J.G., and J.L.J. secured the associated funding.
DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES

Daugherty, A., Manning, M.W., and Cassis, L.A. (2000). Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E deficient mice. J. Clin. Invest. 105, 1605–1612.

Davies, M.J. (1998). Aortic aneurysm formation. Lessons from human studies and experimental models. Circulation 98, 193–195.

Di Gregoli, K., Mohamad Anuar, N.N., Bianco, R., White, S.J., Newby, A.C., George, S.J., and Johnson, J.L. (2017). MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and elastin. Circ. Res. 120, 49–65.

Michel, J.-B., Martin-Ventura, J.L., Egido, J., Sakalihasan, N., Treska, V., Lindholt, J., Allaire, E., Thorsteinsdottir, U., Cockerill, G., Swedenborg, J., et al. (2011). Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc. Res. 90, 18–27.

Nordon, I.M., Hinchliffe, R.J., Loftus, I.M., and Thompson, M.M. (2011). Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat. Rev. Cardiol. 8, 92–102.

Sénémaud, J., Caligiuri, G., Etienne, H., Delbosc, S., Michel, J.B., and Coscas, R. (2017). Translational relevance and recent advances of animal models of abdominal aortic aneurysm. Arterioscler Thromb. Vasc. Biol. 37, 401–410.